Patientenforschung
Anmelden
Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

This research study is looking into a new medicine called crovalimab for people living with Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a very rare blood condition. The main goal is to see how safe crovalimab is and how well it works compared to a treatment already in use, called eculizumab. The study is designed for individuals who are already being treated with similar medications for their PNH. About 190 people are expected to take part. This clinical trial is an important step in understanding if crovalimab could be a new treatment option, offering potential benefits for people affected by PNH.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Hoffmann-La Roche
Einschreibeziel
190
Starten
30 Sep 2020
Geschätzte Fertigstellung
18 Apr 2027
Paroxysmale nächtliche Hämoglobinurie

Worum geht es in dieser Studie?

This study is about a rare blood condition called Paroxysmal Nocturnal Hemoglobinuria, or PNH. PNH happens when red blood cells are destroyed too early, which can lead to symptoms like tiredness, shortness of breath, and tummy pain. Currently, there are treatments available that help manage PNH by blocking a part of the immune system. This study is testing a new medicine, crovalimab, to see if it's a good alternative or improvement to treatments already in use.

The main aim of the study is to carefully look at how safe crovalimab is for people with PNH who are already being treated with similar medicines. It will also compare how well crovalimab works against one of the established treatments, called eculizumab. By doing this, researchers hope to understand if crovalimab could become another helpful option for patients.

This kind of research is very important because it helps doctors and patients make informed decisions about treatment. Finding new medicines that are safe and effective can significantly improve the quality of life for people with rare conditions like PNH. This study is a crucial step in potentially broadening the treatment landscape for this condition.

Wichtige Erkenntnisse

  • Compares a new medicine (crovalimab) to an existing one (eculizumab) for PNH.
  • Aims to check the safety and how well crovalimab works.
  • For PNH patients already on similar complement inhibitor treatments.
  • Involves regular clinic visits and health monitoring.
  • Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.

Wer könnte berechtigt sein?

To join this study, generally, you need to be at least 2 years old and have a confirmed diagnosis of PNH. You should also have been receiving treatment for your PNH, specifically eculizumab or ravulizumab, for at least 3 months before the study starts. Your blood test results (specifically for a protein called Lactate Dehydrogenase) should be within certain limits, and you need to be able to attend all study appointments and follow the instructions given.

There are also some reasons why you might not be able to join. For example, if you've recently had a bone marrow transplant or have certain types of bone marrow disorders, you wouldn't be eligible. The study also cannot include pregnant or breastfeeding individuals, or those planning to become pregnant during or shortly after the study. If you have active Hepatitis B or C, or have recently taken part in another experimental treatment study, that would also prevent you from joining.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you at least 2 years old?
  2. Do you have a confirmed diagnosis of PNH?
  3. Have you been treated with eculizumab or ravulizumab for at least 3 months?
  4. Are you able to attend all study appointments?
  5. Are you not pregnant or breastfeeding, and not planning to become pregnant soon?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you would receive either the new medicine, crovalimab, or the existing medicine, eculizumab. The study team would carefully monitor your health and how you respond to the treatment. This will involve regular visits to the clinic for check-ups, blood tests, and other medical assessments. The total duration of your participation in the study, including the treatment period and follow-up, would be fully explained to you before you agree to join. Women who could become pregnant would also need to agree to use effective contraception during the study and for a period afterwards.

Potenzielle Risiken und Vorteile

Like all clinical studies, taking part has potential benefits and risks. A potential benefit is gaining access to a new treatment option, crovalimab, which might prove to be effective in managing your PNH. Your health would also be closely monitored by medical experts throughout the study. Potential risks could include side effects from the medication or the inconvenience of regular clinic visits and tests. Before you decide, the study team will discuss all known and potential risks and benefits with you in detail. It's important to remember that participating is completely voluntary, and you have the right to withdraw from the study at any time without affecting your usual medical care.

Standorte (80)

  • Carolinas Healthcare System
    Verifizierte Postleitzahl
    Charlotte, Vereinigte Staaten
  • Nationwide Kinderkrankenhaus
    Verifizierte Postleitzahl
    Columbus, Vereinigte Staaten
  • Cliniques Universitaires Saint-Luc
    Verifizierte Postleitzahl
    Brüssel, Belgien
  • AZ Delta Campus Westlaan
    Verifizierte Postleitzahl
    Roeselare, Belgien
  • Chronos Pesquisa Clinica
    Verifizierte Postleitzahl
    Taguatinga, Brazil
  • Santa Casa de Misericordia de Porto Alegre
    Verifizierte Postleitzahl
    Porto Alegre, Brazil
  • Hospital de Clínicas de Porto Alegre X
    Verifizierte Postleitzahl
    Porto Alegre, Brazil
  • Instituto Joinvilense de Hematologia E Oncologia
    Verifizierte Postleitzahl
    Joinville, Brazil
  • Hospital das Clínicas FMRP-USP
    Verifizierte Postleitzahl
    Ribeirão Preto, Brazil
  • *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
    Verifizierte Postleitzahl
    Santo André, Brazil
  • Hospital Sírio-Libanês
    Verifizierte Postleitzahl
    São Paulo, Brazil
  • Hospital Paulistano
    Verifizierte Postleitzahl
    São Paulo, Brazil

Häufige Fragen

What is PNH?

PNH stands for Paroxysmal Nocturnal Hemoglobinuria. It's a rare blood disorder where red blood cells are destroyed too soon, leading to symptoms like tiredness and anaemia.

What are crovalimab and eculizumab?

Crovalimab is a new medicine being tested, and eculizumab is an existing medicine, both used to treat PNH by targeting the immune system.

Who is this study for?

This study is for people with PNH who are already being treated with similar medicines like eculizumab or ravulizumab.

Will I know which medicine I am getting?

Typically in studies like this, you might not know whether you're receiving the new medicine or the existing one. This helps researchers compare the treatments fairly.

Wie lange dauert die Studie?

The exact duration of the study, including treatment and follow-up, will be fully explained by the study team before you decide to participate.

Wie Sie mehr erfahren können

Offizielles Gerichtsprotokoll

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.